NCT07271446 2025-12-09
An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer
Precision Biotech Taiwan Corp.
Phase 1 Completed
Clinical Trials
43 trialsNCT02191891 2025-06-25
Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Boehringer Ingelheim
Phase 1 Completed
NCT01853826 2025-04-11
An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
Boehringer Ingelheim
Phase 3 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT04206787 2025-02-28
The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer
Boehringer Ingelheim
Completed
NCT02597946 2025-02-19
Afatinib in NSCLC With HER2 Mutation
Boehringer Ingelheim
Phase 2 Completed
NCT04795245 2024-12-27
Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma
Boehringer Ingelheim
Completed
NCT02364609 2024-10-16
Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib
University of California, Davis
Phase 1 Completed
NCT04750824 2024-09-19
Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.
Boehringer Ingelheim
Completed
NCT01542437 2024-02-06
NSCLC
Instituto Nacional de Cancerologia de Mexico
Phase 2 Completed
NCT02795156 2023-12-05
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02183883 2023-11-29
DARWIN1
University College, London
Phase 2 Completed
NCT03727724 2023-10-18
AFACET
The Netherlands Cancer Institute
Phase 2 Completed
NCT04179890 2023-05-25
UpSwinG
Boehringer Ingelheim
Completed
NCT04201756 2022-12-23
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Completed
NCT02716311 2022-08-11
ACE-Lung
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT02440854 2022-04-27
Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings
Boehringer Ingelheim
Completed
NCT01156545 2022-04-06
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
National Cancer Center, Korea
Phase 2 Completed
NCT04552535 2022-01-11
A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
Boehringer Ingelheim
Completed
NCT02629523 2021-08-03
LiquidLung-A
Chonnam National University Hospital
Phase 2 Completed
NCT03370770 2020-12-24
Afatinib Osimertinib Sequencing NIS
Boehringer Ingelheim
Completed
NCT04640870 2020-12-23
The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib
Hellenic Cooperative Oncology Group
Completed
NCT01999985 2020-11-27
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01466660 2020-04-07
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Boehringer Ingelheim
Phase 2 Completed
NCT02514174 2020-03-30
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Boehringer Ingelheim
Phase 4 Completed
NCT02047903 2020-01-09
GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations
Boehringer Ingelheim
Completed
NCT01953913 2019-08-12
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
Boehringer Ingelheim
Phase 3 Completed
NCT02145637 2019-03-29
Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)
Yonsei University
Phase 1 Completed
NCT01523587 2019-02-15
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
Boehringer Ingelheim
Phase 3 Completed
NCT01415011 2019-01-15
TIMELY
University College, London
Phase 2 Completed
NCT02208843 2018-12-17
Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Boehringer Ingelheim
Phase 4 Completed
NCT01121393 2018-12-14
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
Boehringer Ingelheim
Phase 3 Completed
NCT02131259 2018-09-07
Long-term Observation PMS for Afatinib
Boehringer Ingelheim
Completed
NCT00949650 2018-04-06
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Boehringer Ingelheim
Phase 3 Completed
NCT01074177 2018-03-09
Understanding Mechanisms of Acquired Resistance to BIBW2992
Massachusetts General Hospital
Phase NA Completed
NCT02044380 2017-03-31
Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations
Boehringer Ingelheim
Phase 3 Completed
NCT01814553 2016-10-31
ADAM-Afatinib Diarrhea Assessment and Management
Boehringer Ingelheim
Phase 3 Completed
NCT00525148 2016-09-16
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
Boehringer Ingelheim
Phase 2 Completed
NCT00656136 2016-07-26
BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)
Boehringer Ingelheim
Phase 3 Completed
NCT01090011 2015-10-02
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT00711594 2015-01-15
LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
Boehringer Ingelheim
Phase 2 Completed
NCT00730925 2014-03-26
Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients
Boehringer Ingelheim
Phase 2 Completed
NCT01003899 2013-12-31
A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]
Boehringer Ingelheim
Phase 2 Completed